Source: Guideline 2011



Rating:

Share or cite this content

Citations should be made in the following way:
B.L. Laube, H.M. Janssens, F.H.C. de Jongh, et al.. What the pulmonary specialist should know about the new inhalation therapies. Guideline 2011

Member's Comments

Beatrice Konamah - 06.07.2013 00:09
excellent material

Related content which might interest you: What the pulmonary specialist should know about the new inhalation therapies Source: Eur Respir J 2011; 37: 1308-1417 Year: 2011 What does the future hold for pulmonary rehabilitation? Source: Eur Respir Monogr 2021; 93: 311-325 Year: 2021 Pathophysiology of pulmonary hypertension: what the interested clinician needs to know Source: ERS Course 2020 - Pulmonary hypertension and pulmonary vascular disease Year: 2020 Improving symptomology in COPD: which therapy would you choose, a brochodilator or pulmonary rehabilitation? Source: International Congress 2019 – Hot topics in pulmonary rehabilitation Year: 2019 Goal-oriented therapy in paediatric pulmonary arterial hypertension: are we ready? Source: Eur Respir J 2014; 44: 1404-1407 Year: 2014 Assessing pulmonary hypertension severity in lung disease is a key step to improving outcomes: embrace resistance and don't be pressurised to go with the flow Source: Eur Respir J, 58 (2) 2102008; 10.1183/13993003.02008-2021 Year: 2021 Are we ready for home treatment of acute pulmonary embolism? Source: International Congress 2014 – Current controversies in the management of acute pulmonary embolism Year: 2014 What happens after pulmonary rehabilitation? Source: Eur Respir Monogr 2021; 93: 218-230 Year: 2021 Is there room for further innovation in inhaled therapy for airways disease? Source: Breathe, 14 (3) 216; 10.1183/20734735.020318 Year: 2018 Predicting physician decision to prescribe systemic corticosteroids following an exacerbation of airways disease Source: International Congress 2019 – Clinical approach to asthma management Year: 2019 An evidence-based and step-wise approach to treat pulmonary sarcoidosis with old and new drugs Source: International Congress 2019 – State of the art session: Interstitial lung diseases Year: 2019 COPD guides and inhaled corticosteroids. Is there an adequate use in primary care? Source: International Congress 2016 – Targeting care, pulmonary rehabilitation, management, and self-management of COPD exacerbations in primary care Year: 2016 “I don’t think there’s a simple way of doing it:” the use of an electronic alert to identify excessive prescribing of short-acting beta2-agonists for people with asthma – a qualitative study with asthma experts and primary care staff Source: Virtual Congress 2020 – Diagnosis and management of airways disease in primary care Year: 2020 Physicians’ and patients’ expectations of therapies for pulmonary arterial hypertension: where do they meet? Source: Eur Respir Rev 2014; 23: 458-468 Year: 2014 Expanding the scope of pulmonary rehabilitation Source: Annual Congress 2005 - The ERS/ATS statements on pulmonary rehabilitation Year: 2005 The effectiveness of pulmonary rehabilitation including occupational therapy in patients with chronic pulmonary emphysema Source: Eur Respir J 2002; 20: Suppl. 38, 376s Year: 2002 Whither pulmonary rehabilitation? Will alternative modes help or hurt? Source: Eur Respir J, 52 (4) 1801678; 10.1183/13993003.01678-2018 Year: 2018 Repurposing benzbromarone for pulmonary arterial hypertension: can channelling the past deliver the therapy of the future? Source: Eur Respir J, 53 (6) 1900583; 10.1183/13993003.00583-2019 Year: 2019